Introduction {#Sec1}
============

Globally, 130--150 million people are estimated to be chronically infected with hepatitis C virus (HCV) \[[@CR1]\]. In developed countries, injecting drug use typically accounts for 20--40% of HCV infections \[[@CR2]\]; the prevalence of hepatitis C antibodies in people who inject drugs (PWIDs) is estimated at 67% worldwide \[[@CR3]\]. High-risk behaviors among PWIDs (sharing needles, syringes, and other equipment) are common, and are responsible for a high proportion of ongoing transmission in many regions. Among current PWIDs in Europe, median incidence of community-acquired HCV infection is approximately 26 infections per 100 person-years \[[@CR3]\]. Furthermore, rates of reinfection following viral clearance are estimated to be between 1.8 and 46.7 cases per 100 person-years \[[@CR4]\]. Therefore, comprehensive implementation of harm reduction strategies, together with broad access to treatment for this patient population, have the potential to play a key role in the elimination of HCV \[[@CR4]\].

However, despite modeling studies indicating the utility of effective treatment in preventing HCV transmission among PWIDs \[[@CR5]\], reluctance on the part of clinicians to treat this vulnerable population means that treatment rates have historically been suboptimal \[[@CR6]\].

Studies using dual peg-interferon and ribavirin (Peg-IFN/RBV) therapy in PWID have demonstrated high adherence \[[@CR7], [@CR8]\], highlighting the potential for such patients to sustain a complex regimen over a long duration. However, challenges associated with retention in care, particularly following treatment completion, mean that the full benefits of treatment may not be realized or reflected in reported data.

In 2013, when our study was designed, there were no data available in PWIDs treated with the first-generation direct-acting antivirals (DAAs), telaprevir and boceprevir. These two drugs, in combination with Peg-IFN and RBV, increased virologic cure rates but at the expense of additional toxicity compared to Peg-IFN and RBV alone \[[@CR9], [@CR10]\]. The more recent introduction of highly effective and well-tolerated IFN-free DAA combinations for HCV treatment has made HCV elimination in PWIDs a plausible near-future scenario \[[@CR11], [@CR12]\]. Improved understanding of considerations around adherence to therapy and retention in care among this challenging population could lead to improved patient outcomes and important public health benefits. The aims of this study were to evaluate the effectiveness, safety, and adherence to telaprevir combined with Peg-IFN and ribavirin in patients with a history of injecting drug use and who were chronically infected with genotype 1 (GT1) HCV.

Methods {#Sec2}
=======

Design and Eligibility Criteria {#Sec3}
-------------------------------

INTEGRATE was a prospective, multicenter, non-interventional, single-arm study of telaprevir with Peg-IFN/RBV in adult patients chronically infected with HCV GT1 who had a history of injecting drug use and any fibrosis stage including compensated cirrhosis. Patients had recent documentation (within 18 months) of the degree of liver fibrosis (METAVIR F0--F4; Ishak 0--6), assessed by liver biopsy or non-invasive test (e.g., FibroTest, Fibroscan) \[[@CR13], [@CR14]\]. Patients were receiving opioid substitution therapy (OST; e.g., methadone or buprenorphine) and/or were followed in an addiction center/program. Patients were treatment-naïve or prior relapsers to IFN (pegylated or not) and RBV therapy; patients with prior history of DAA therapy were ineligible. In addition, patients with decompensated liver disease, active hepatitis B infection, HIV coinfection, or infection with HCV other than GT1 were excluded from the study, as were patients with contraindications to telaprevir, Peg-IFN or RBV.

Setting {#Sec4}
-------

The study was conducted from 13 May 2013 to 9 February 2015 at 18 sites in 6 countries: Belgium (6 sites), France (3 sites), Germany (4 sites), Netherlands (1 site), Switzerland (1 site), and Kingdom (3 sites). Participating physicians offered enrollment in this study to all eligible patients at their site in whom they planned to initiate therapy with telaprevir and Peg-IFN/RBV.

The study was reviewed and approved by Independent Ethics Committees and conducted in accordance with the Helsinki Declaration of 1964, as revised in 2008 and 2013, and Good Clinical Practice guidelines. All patients provided written, informed consent prior to the start of the study (clinicaltrials.gov NCT01980290).

Procedures {#Sec5}
----------

Due to the non-interventional nature of the study, patient care and treatment followed local standard as well as HCV drug labels. Patients received telaprevir with Peg-IFN/RBV for 12 weeks, followed by either 12 or 36 weeks of Peg-IFN/RBV alone. Study drugs were not provided by the sponsor.

Prospective data were recorded at six time points for each patient (corresponding to routine care visits): inclusion, and at the patient's routine care visit closest to Weeks 4, 12, 24, end-of-treatment, and end-of-follow-up (approximately 12 weeks after end-of-treatment). No additional blood, urine, or other biological samples were required, and no additional investigations, beyond the routine clinical management of the patient, were performed.

Objectives {#Sec6}
----------

The pre-defined primary objective was to evaluate effectiveness based on sustained virologic response, defined as plasma HCV RNA level \<25 IU/mL 12 weeks after last dose of study medication (SVR12). No formal hypothesis testing was performed in association with this primary objective owing to the non-comparative design of the study; inclusion of a comparator arm was deemed unethical.

Plasma HCV RNA was quantified using locally available assays such as the Roche High Pure COBAS^®^ TaqMan^®^ 2.0 or Abbott RealTime HCV assays. The lower limit of quantification was, or was imputed to be, 25 IU/mL for all assays used.

Efficacy was assessed in the intent-to-treat (ITT) and per protocol evaluable-for-effectiveness (EE) populations. The ITT population comprised all patients who received at least one dose of telaprevir and had ≥1 post-baseline efficacy or safety assessment, while the EE population excluded patients with major protocol deviations plausibly affecting effectiveness, patients lost to follow-up and patients who completed the study but had missing HCV RNA at the SVR12 timepoint.

Secondary objectives included assessment of tolerability, safety, and adherence. Adherence was assessed using the self-reported, validated M-MASRI questionnaire \[[@CR15]\]; assessment of pill/vial counts was also included in the protocol. For the M-MASRI questionnaire, a horizontal visual analogue scale was used to generate a self-rated adherence measure (% of doses received/total) for each of Peg-IFN, RBV and telaprevir. Excessive alcohol consumption was evaluated using the self-reported alcohol use disorders identification test (AUDIT) developed by the World Health Organization \[[@CR16], [@CR17]\].

Statistical Methods {#Sec7}
-------------------

Based on an expected response rate of 60% with the telaprevir-based regimen, it was calculated (based on exact binomial distribution and using the Clopper--Pearson formula) that a sample size of 80 evaluable patients would give a 2-sided 95% confidence interval extending 11% above and below the expected observed response rate of 60%. To allow for up to 30% of patients to have non-evaluable data (i.e., as-treated or observed analyses do not impute missing data) for the primary virologic endpoint, enrollment of 115 patients was planned.

Results {#Sec8}
=======

A total of 49 adult patients with a history of injection drug use and chronic HCV GT1 infection were enrolled in the study. Enrollment was lower than expected due to alternative treatments becoming available in the participating countries. Of the 49 patients, 46 had post-baseline assessments and were included in the ITT analysis (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). All ITT patients received 1125 mg twice-daily telaprevir (oral). 93% (43/46) of patients received Peg-IFN alfa 2a (180 µg/week, subcutaneously) and 7% (3/46) received Peg-IFN alfa 2b (100--150 µg/week, subcutaneously). In addition, 96% (44/46) received an initial oral RBV dose of 1000 or 1200 mg/day, and 4% (2/46) received initial doses ≤800 mg/day.Fig. 1Patient disposition. *Asterisk* ITT population is defined as all patients treated with telaprevir and having at least one post-baseline effectiveness or safety assessment. Of the 49 patients who were treated, 46 had post-baseline assessments and were included in the ITT population. *AE* adverse event, *ITT* intent-to-treat, *LTFU* lost to follow-up Table 1Baseline demographics and disease characteristicsTreatment naïve (*n* = 43)Prior relapsers (*n* = 3)Total (*n* = 46)Median age, years (range)43 (28--57)47 (44--56)44 (28--57)Age ≤45 years, *n* (%)27 (63)1 (33)28 (61)Caucasian, *n* (%)39 (91)3 (100)42 (91)Male, *n* (%)37 (86)3 (100)40 (87)Body mass index (kg/m^2^) Median (range)25 (17--36)26 (22--27)25 (17--36)HCV subtype, *n* (%) 1a34 (79)3 (100)37 (80) 1b7 (16)07 (15) Other (unspecified)2 (5)02 (4)Fibrosis stage, *n* (%) F0--115 (35)1 (33)16 (35) F27 (16)07 (15) F34 (9)1 (33)5 (11) F47 (16)07 (15) Unknown10 (23)1 (33)11 (24)Baseline VL ≥800,000 IU/mL, *n* (%)26 (61)2 (67)28 (61)Patients on OST during pre-treatment phase, *n* (%)31 (72)3 (100)34 (74) Methadone^a^25 (58)2 (67)27 (59) Buprenorphine^b^6 (14)1 (33)7 (15)Patients on OST during treatment phase, *n* (%)39 (91)3 (100)42 (91) Methadone^a^30 (70)2 (67)32 (70) Buprenorphine^b^9 (21)1 (33)10 (22)Heroin and/or cocaine use, *n* (%)35 (81)2 (67)37 (80)Crack cocaine use, *n* (%)3 (7)03 (7)Methamphetamine use, *n* (%)2 (5)02 (4)Morphine or other opioids use, *n* (%)1 (2)01 (2)Last time heroin and/or cocaine used, *n*35237 Within the last month, *n* (%)8 (23)08 (22) 1--6 months ago, *n* (%)3 (9)03 (8) More than 6 months, *n* (%)24 (69)2 (100)26 (70)Psychiatric comorbidity, active (any), *n* (%)16 (37)1 (33)17 (37) Depression9 (21)1 (33)10 (22) Anxiety6 (14)06 (13) Psychosis, schizophrenia2 (5)02 (4)Patients using concomitant psychiatric therapies, *n* (%)18 (42)018 (39) Benzodiazepine derivatives13 (30)013 (28) Other antidepressants12 (28)012 (26) Other anxiolytics1 (2)01 (2)Alcohol use disorders identification test (AUDIT) score at baseline, *n*34236 ≥8^c^, *n* (%)14 (41)1 (50)15 (42) Mean (SE)9.0 (1.6)15.5 (15.5)9.4 (1.6)*HCV* hepatitis C virus, *OST* opioid substitution therapy, *VL* viral load^a^Methadone category includes methadone, methadone hydrochloride and levomethadone hydrochloride^b^Buprenorphine category includes buprenorphine, buprenorphine hydrochloride and buprenorphine with naloxone^c^A score ≥ 8 is associated with harmful or hazardous drinking

Patients included in the ITT population were mainly white (91%), male (87%) and ≤45 years old (61%). Most patients were infected with HCV GT1a (80%), non-cirrhotic (85%) and treatment-naïve (93%). Of the patients, 74% were on OST during pre-treatment phase, and 91% during treatment phase, while 80% reported a history of heroin and/or cocaine use, of whom 22% had last used them in the previous month and 70% more than 6 months ago. Also, 37% of patients had an active concomitant psychiatric condition, mainly depression and anxiety (Table [1](#Tab1){ref-type="table"}).

Of the total patients, 43% (20/46) discontinued treatment prematurely (Fig. [1](#Fig1){ref-type="fig"}). The two main reasons were loss to follow-up (8/46; 17%) and adverse event (AE) (6/46; 13%).

Overall, the SVR12 rate was 54% (95% CI 39, 69; 25/46) in the ITT population and 74% (95% CI 56, 87; 25/34) in the EE population (Table [2](#Tab2){ref-type="table"}). In the ITT population, 91% (42/46) patients experienced at least one on-treatment AE, and 24% (11/46) experienced one or more serious AE(s). The only serious AE occurring in more than one patient was anemia (*n* = 2). The most frequently reported AEs, occurring in more than 20% of patients in the ITT population, were anemia (39%), thrombocytopenia (30%), leukopenia (30%), fatigue (26%), and pruritus (22%).Table 2Summary of treatment outcomesTreatment outcome, *n* (%)ITT population, *n* = 46EE population, *n* = 34SVR1225 (54)25 (74)Relapse1 (2)1 (3)Viral breakthrough1 (2)1 (3)Other19 (41)7 (21)*ITT* Intent-to-treat population. Ttreatment outcome *Other* (*n* = 19): 2 had HCV RNA \>25 IU/mL at SVR time point but neither had a relapse nor viral breakthrough and 17 patients had missing data within the follow-up Week 12 window (8 lost to follow-up, 3 completed treatment but had no HCV RNA at SVR12 timepoint, 1 protocol violation, 1 consent withdrawal, 2 premature discontinuations due to AE, 2 Other*EE* Evaluable for effectiveness population, excluding patients lost to follow-up, patients who completed treatment but did not have HCV RNA assessment available at SVR12 time point, and patients with major protocol deviations plausibly affecting effectiveness; 12 patients were excluded from the EE population: 8 LTFU, 3 who completed treatment but had no HCV RNA available at SVR12 time point, and 1 who was a previous Null responder who received boceprevir instead of telaprevir (protocol violation). Treatment outcome *Other* (*n* = 7): 2 patients had HCV RNA \>25 IU/mL at SVR12 time point but neither had a relapse nor viral breakthrough, 5 discontinued treatment prematurely (2 AEs, 1 patient withdrawal, 2 other) and had no HCV RNA available after discontinuation

Mean adherence to telaprevir, Peg-IFN and RBV was \>91% at Weeks 4 and 12 among patients who responded to the M-MASRI questionnaire, and mean adherence to Peg-IFN/RBV was \>89% at end of treatment (Table [3](#Tab3){ref-type="table"}). Adherence could not be measured by pill/vial count, as initially planned in the protocol, because most patients did not return their used medication packages.Table 3Adherence to treatment throughout the study period as determined by the M-MASRI questionnaireTotal (*n* = 46)Telaprevir Patients with adherence data at Week 4, *n*32 Mean (SD)95.6 (7.80) Median (range)100 (70, 100) Patients with adherence data at Week 12, *n*22 Mean (SD)94.7 (12.56) Median (range)100 (50, 100)Peg-IFN Patients with adherence data at Week 4, *n*29 Mean (SD)97.2 (9.60) Median (range)100 (50, 100) Patients with adherence data at Week 12, *n*21 Mean (SD)97.6 (8.89) Median (range)100 (60, 100) Patients with adherence data at EOT, *n*20 Mean (SD)94.8 (21.24) Median (range)100 (5, 100)RBV Patients with adherence data at Week 4, *n*28 Mean (SD)95.9 (8.17) Median (range)100 (70, 100) Patients with adherence data at Week 12, n18 Mean (SD)91.1 (17.03) Median (range)100 (30, 100) Patients with adherence data at EOT, n19 Mean (SD)89.7 (22.92) Median (range)100 (5, 100)*EOT* end of treatment, *IFN* interferon, *RBV* ribavirin, *SD* standard deviation

Mean (SE) alcohol consumption score at baseline, as assessed by AUDIT questionnaire, was 9.4 (1.63). Alcohol consumption among patients in the ITT population decreased during the treatment phase (Week 12: 7.1; 1.57; Week 24: 7.1; 2.75).

Discussion {#Sec9}
==========

Our prospective, observational study showed a SVR rate of 54% (ITT population; 74% EE population) in patients with a history of injecting drug use chronically infected with HCV genotype 1 HCV. Our findings were consistent with the virologic cure rates and safety profile of telaprevir combined with Peg-IFN/ribavirin obtained in a large HCV-TARGET real-world cohort \[[@CR18]\].

Our results shed important light on the challenges associated with treating HCV in patients with a history of injecting drug use. The high rate of premature discontinuation, mainly due to loss to follow-up (17%) and adverse events (13%), is noteworthy. The complexity of the regimen, and its relatively poor safety profile (compared with IFN-free combination therapies), may have contributed to this high drop-out rate. However, patients who were lost to follow-up did not withdraw consent, but rather ceased to attend the study center for regular care.

Our study has several limitations. Firstly, recruitment was lower than expected owing to the extremely rapid evolution of hepatitis C treatments between 2011 and 2014 and the advent of IFN-free combination therapies, which now represent the standard-of-care in most regions. As a consequence of the superior efficacy and safety profiles of IFN-free combinations, IFN-based triple therapies such as the telaprevir and Peg-IFN/RBV combination are now obsolete. Secondly, compliance to treatment could only be measured by self-reported adherence as most patients did not bring back their packages to the institution, hindering the interpretation of our adherence data. However, the observed SVR rate in the EE population (74%) suggests that on-treatment compliance was good, since it is similar to the 75% SVR rate obtained in the ADVANCE registrational clinical trial \[[@CR9]\]. Our inability to perform pill/vial counts illustrates the challenges associated with the management of this patient population, reflecting real-world clinical practice, in contrast with the highly selected patients typically enrolled in interventional randomized controlled trials.

Post-hoc analyses of recent interventional clinical trials investigating IFN-free combinations have reported very high treatment completion and SVR rates (both \>90%) in patients on OST \[[@CR19], [@CR20]\]. The interventional C-EDGE CO-STAR study, which was conducted exclusively in patients on OST, confirmed these findings as only 3% (10/296) of patients were lost to follow-up during the 12-week post-treatment period. In contrast, 11--13% loss-to-follow-up rates have been reported in some recent real-world studies conducted in PWIDs (on OST or not) treated with IFN-free combinations \[[@CR21], [@CR22]\].

One possible reason for this discrepancy in dropout rates relates to the stringent patient selection criteria typically applied in interventional trials, but less so in observational studies. For example, the C-EDGE CO-STAR study only enrolled patients on OST who had a documented compliance to appointments of at least 80% \[[@CR12]\]. However, recent real-world studies have demonstrated that low loss-to-follow-up rates and high SVR rates (exceeding 90%) can be achieved in PWIDs receiving integrated care from multidisciplinary teams \[[@CR23], [@CR24]\], and that rates of treatment completion and SVR comparable with the general patient population can be achieved in active drug users and patients receiving OST \[[@CR25]\]. These findings support the provision of DAA therapy to such patients, the treatment of whom is key to achieving the goal of elimination of HCV transmission \[[@CR25]\].

Strategies to improve adherence and boost continuity of care in PWIDs are essential if successful outcomes are to be achieved in these patient populations, not only to ensure that they are cured but also to prevent reinfection and minimize ongoing transmission \[[@CR26]\]. Such strategies could include incentivizing patients, implementing directly-observed therapy or other individualized approaches.

Conclusion {#Sec10}
==========

Despite a substantial treatment discontinuation rate (including loss-to-follow-up), self-reported on-treatment adherence to telaprevir combined with Peg-IFN and ribavirin was high and virologic cure rates were similar to those seen in large real-world cohorts. This indicates that people with a history of injecting drugs should not be refused treatment and suggests that improving retention in care is necessary to facilitate appropriate medical follow-up.
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